Shares of Omeros Corp. (OMER) are up over 170% today following the announcement of a definitive asset purchase and licensing agreement with Novo Nordisk (NVO) for Omeros' investigational drug, Zaltenibart.
Zaltenibart, which is in clinical development for the treatment of rare blood and kidney disorders, will now be exclusively developed and commercialized by Novo Nordisk across all potential indications under the terms of the deal. In return, Omeros is eligible to receive $340 million in upfront and near-term milestone payments, up to a total of $2.1 billion, including potential development and commercial milestones, plus tiered royalties on net sales.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.